Related coverage linked through entity extraction aliases.
Feb 14, 2026
Multiple Indian drugmakers begin selling generic versions of Ozempic and Wegovy following March patent expiration, with prices 50-60% below branded counterparts. The launches signal global pricing shifts as Novo Nordisk faces patent losses across multiple markets.
Feb 13, 2026
New research shows semaglutide cuts cardiovascular event risk by 4% per 5kg weight loss, with two-thirds of heart benefits unexplained by weight reduction alone. Study of 17,604 participants suggests multiple protective mechanisms beyond weight loss.
Feb 13, 2026
Recent studies demonstrate tirzepatide's efficacy extends beyond diabetes management, showing reduced glaucoma risk in diabetic patients and significant improvements in pediatric Type 2 diabetes treatment with superior weight loss outcomes.
Feb 13, 2026
Natco Pharma has received approval from India's CDSCO to manufacture and market generic semaglutide injection, with a March 2026 launch planned. The approval comes amid patent litigation and intense competition in India's rapidly expanding diabetes and obesity drug market.
Feb 13, 2026
Real-world study finds SGLT2 inhibitors reduce chronic kidney disease and acute kidney injury risk more effectively than GLP-1 receptor agonists in patients with type 2 diabetes, with greatest benefits in those without preexisting kidney disease.
Feb 13, 2026
A study published in JAMA Cardiology found that semaglutide would be cost-effective for secondary cardiovascular disease prevention in U.S. adults with overweight or obesity at an 18% price reduction or at the current cash price of $5,988 annually.
Feb 14, 2026
Novo Nordisk launched oral Wegovy in January 2026 with strong early uptake, but faces FDA criticism over misleading advertising and legal battles over compounded alternatives as the company projects sales decline for 2026.
Apr 21, 2025
Orforglipron, an oral non-peptide GLP-1R partial agonist developed by Chugai and Eli Lilly, has reported positive Phase III data for obesity and type 2 diabetes, representing a shift from injectable peptides to oral small molecules in the GLP-1R space.
Dec 19, 2025
Eli Lilly has built $1.5 billion in pre-launch inventory of oral weight loss drug orforglipron ahead of an April 2026 FDA decision, while Phase 3 data showed the drug maintained weight loss after switching from injectables.
Feb 13, 2026
The FDA announced plans to restrict non-FDA-approved compounded GLP-1 drugs mass-marketed as alternatives to approved weight loss medications, citing safety concerns and misleading advertising practices.
Feb 13, 2026
Dr Reddy's and Biocon plan to launch generic versions of Novo Nordisk's weight-loss drugs at up to 60% below branded prices as semaglutide patents expire, targeting a global market projected to reach $150 billion by the early 2030s.
Feb 10, 2026
Hims and Hers Health pulled its $49 compounded version of Novo Nordisk's Wegovy weight-loss pill after the FDA referred the company to the Department of Justice for potential legal violations.
Dec 22, 2025
A nationwide study of US veterans with type 2 diabetes found semaglutide initiation more than doubled the risk of nonarteritic anterior ischemic optic neuropathy compared to SGLT2 inhibitors, though absolute risk remained low at 0.29%.
